Amino-Terminal Pro-Brain Natriuretic Peptide to Diagnose Congestive Heart Failure in Patients With Impaired Kidney Function  by Lamb, Edmund J. et al.
Costanzo et al. (1) point out the advantages of greater safety
and shorter admissions with their treatment. Perhaps a resurrec-
tion of the use of Southey tubes would be even less costly and at
least as safe, and would be affordable in third-world countries. It is
gratifying to learn of this advance made possible by physiologic
reasoning, instead of ever-more complicated and expensive tech-
nology.
A final comment: there appears to be a tautology in the title of
the investigators’ study (1). Doesn’t decompensated mean the same
as heart failure? Why not just “diuretic-resistant heart failure”?
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We thank Dr. Guntheroth for his clinical observation and for
raising consideration of the relation between central venous pres-
sure and glomerular filtration rate based on our study (1). The
inverse relation between right atrial pressure and glomerular
filtration rate has been exquisitely documented, with animal
studies demonstrating decreasing glomerular filtration rates with
increased right atrial pressure (2–4). Similarly, glomerular filtra-
tion rates increase when normal human subjects are subjected to
decreased central venous pressure by lower body negative pressure
(5). Reduction of central venous filling pressures with Southey
tubes, rotating tourniquets, or medicinal leeches could improve
glomerular filtration rates. The mechanism of diuresis following
Southey tube placement may be more insidious, however, as it is
possible that the discomfort of the procedure stimulates catechol-
amine release, which, in turn, improves cardiac function and renal
blood flow.
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Amino-Terminal Pro-Brain
Natriuretic Peptide to Diagnose
Congestive Heart Failure in Patients
With Impaired Kidney Function
We were interested in the data of Anwaruddin et al. (1) demon-
strating that in a group of patients presenting with dyspnea, of
whom approximately one-third had chronic kidney disease
(CKD), there was a strong relationship between amino-terminal
pro-brain natriuretic peptide (NT-proBNP) and glomerular filtra-
tion rate (GFR) (r  0.55), which remained independently
highly significant in their multiple regression analysis. Despite this,
Anwaruddin et al. (1) conclude that the diagnostic performance of
NT-proBNP for congestive heart failure (CHF) is unaffected by
the concomitant presence of kidney disease.
We have presented comparative data on the effect of BNP and
NT-proBNP in a cohort of patients with CKD with a range of
GFR between 5 and 60 ml/min/1.73 m2 but not yet treated with
dialysis, the majority of whom did not have CHF, thereby
providing an opportunity to focus on the effect of diminishing
GFR (2). The relationship between GFR and NT-proBNP was
similar to that described by Anwaruddin et al. (rs  0.53),
whereas that for BNP was less strong (rs  0.36). Anwaruddin
and colleagues also report a weaker relationship between GFR and
BNP (r  0.18), although their BNP data were limited to those
patients known to have CHF. Using a multiple regression ap-
proach we quantified the relationship between GFR and natri-
uretic peptide concentrations: for each 10 ml/min/1.73 m2 decline
in GFR, a 21% increase in BNP could be anticipated, compared to
a 38% increase in NT-proBNP. We concluded that the effect of
declining GFR on natriuretic peptide concentration was greater for
NT-proBNP than for BNP. This is explicable from an under-
standing of the basic biology of these co-secreted peptides, with
BNP having several known pre-renal clearance mechanisms in
addition to renal elimination, whereas NT-proBNP is believed to
be cleared by glomerular filtration alone.
How could 2 such similar datasets arrive at opposite conclu-
sions? Anwaruddin et al. used NT-proBNP in a “rule-in” mode for
heart failure, whereas in many studies and practical health service
applications, lower thresholds have been proposed to enable use of
the test in rule-out mode—a negative test result suggesting further
investigation for heart failure (e.g., echocardiography) is probably
unwarranted (3). The diagnostic thresholds they have selected
(450 pg/ml at 50 years and 900 pg/ml at 50 years) are
therefore higher than the manufacturer’s usual decision thresholds.
Despite this, however, 32% of patients with CKD (GFR 60
ml/min/1.73 m2) and no CHF had NT-proBNP concentrations in
excess of these thresholds. An upward revision of the cut-point for
CKD patients to 1200 pg/ml slightly reduced this nonspecificity
such that 28% of CKD patients with NT-proBNP concentrations
1,200 pg/ml did not have CHF: however, this would generally
not be considered acceptable performance for a diagnostic test used
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in clinical decision making. We would expect poor performance if
NT-proBNP were to be used for rule-out decisions in patients
with reduced GFR.
It is unfortunate that the investigators (1) did not undertake
BNP testing in their entire cohort so that true comparative
diagnostic performance could be evaluated. On the basis of their
data, we would disagree with their conclusion that NT-proBNP is
useful for diagnosing CHF across a wide range of renal functions.
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Lamb and colleagues attempt to compare the results of our study
to their previously published (1) data, derived from a small cohort
of nondyspneic subjects (the vast majority of whom did not have
heart failure [HF]). These comparisons are uninformative, and the
more appropriate approach would be to examine our data in the
context of the currently available data examining the utility of
B-type natriuretic peptide (BNP) in the breathless patient (with
and without HF) (2).
In our study, the area under the receiver operating characteristic
curve (AUC) for amino-terminal pro-B-type natriuretic peptide
(NT-proBNP) for diagnosis of acute HF in those with moderate
or worse chronic kidney disease (CKD) was 0.88, comparable to
the data from such patients in the Breathing Not Properly
Multinational Study renal analysis (AUC between 0.81 and 0.86)
(2). It is of great interest to us that specificity for BNP in those
with CKD was not reported (2); however, with such similar AUC,
there is little chance that the specificity of BNP in those with CKD
is any different than demonstrated for NT-proBNP in our study.
We point out that the specificity of NT-proBNP1200 pg/ml for
acute HF in patients with CKD was 72%, comparing favorably to
the overall specificity of 76% reported among all subjects in the
Breathing Not Properly Multinational Study of BNP (3). As well,
NT-proBNP 300 pg/ml had 100% negative predictive value in
patients with CKD in our study, and concentrations of NT-
proBNP were also strongly prognostic in those with CKD.
Thus, although correlations between renal function and BNP or
NT-proBNP may differ, at optimal cut-points it would be rather
hard to argue that a clinically meaningful difference between BNP
and NT-proBNP exists in those with CKD, and the assertion by
Lamb and colleagues that NT-proBNP has “unacceptable perfor-
mance” in the patient with CKD is not accurate.
Lamb and colleagues quite incorrectly suggest that we asserted
NT-proBNP testing to be “unaffected” by renal function. We
emphasized the effects of renal function on NT-proBNP, but
concluded “even in the presence of impaired renal function,
NT-proBNP measurement is a valuable tool for the diagnostic and
prognostic evaluation of dyspneic patients,” a conclusion supported
by our data.
Whereas observational studies demonstrate that CKD leads to
elevations in both BNP and NT-proBNP (with modest differences
with respect to the magnitude of elevation of each), it is dangerous
to necessarily ascribe such phenomena entirely to differential depen-
dence on renal clearance. Indeed, early mechanistic studies of renal
function and natriuretic peptides suggest the kidneys clear both
markers equally (and at only 20%) (4).
The interaction between natriuretic peptides and CKD is a
complex one; we concede the potential for difficulties in interpre-
tation of NT-proBNP concentrations in those with impaired
kidney function, but we strenuously emphasize that this is a
circumstance that also hinders use of BNP (5). In summary, the
available data do not support a clinically meaningful difference
between NT-proBNP and BNP in those with CKD, and the data
contradict the tacit suggestion by Lamb and colleagues that BNP
is superior to NT-proBNP in those with impaired renal function.
*James L. Januzzi, MD, FACC
Donald M. Lloyd-Jones, MD, ScM, FACC
Saif Anwaruddin, MD
*Massachusetts General Hospital
Cardiology/Internal Medicine
Yawkey 5984
55 Fruit Street
Boston, Massachusetts 02114
E-mail: jjanuzzi@partners.org
doi:10.1016/j.jacc.2006.06.018
REFERENCES
1. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP)
and amino-terminal proBNP in patients with CKD: relationship to
renal function and left ventricular hypertrophy. Am J Kidney Dis
2005;46:610–20.
2. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide
and renal function in the diagnosis of heart failure: an analysis from the
Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;
41:571–9.
3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of
B-type natriuretic peptide in the emergency diagnosis of heart failure.
N Engl J Med 2002;347:161–7.
4. Schou M, Dalsgaard MK, Clemmesen O, et al. Kidneys extract BNP
and NT-proBNP in healthy young men. J Appl Physiol 2005;99:
1676–80.
5. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide
for acute dyspnea in patients with kidney disease: insights from a
randomized comparison. Kidney Int 2005;67:278–84.
1061JACC Vol. 48, No. 5, 2006 Correspondence
September 5, 2006:1054–63
